Area riservata
CRF icona.org
Contatti
2015
- A Cozzi-Lepri, M Noguera-Julian, F Di Giallonardo, R Schuurman, M Daumer, S Aitken, F Ceccherini-Silberstein, A d'Arminio Monforte, AM Geretti, CL Booth, R Kaiser, C Michalik, K Jansen, B Masquelier, P Bellecave, RD Kouyos, E Castro, H Furrer, A Schultze, HF Gunthard, F Brun-Vezinet, R Paredes, KJ Metzner. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. J Antimicrob Chemother. 2015;70:930-940.
2012
- A Lai, FR Simonetti, G Zehender, A De Luca, V Micheli, P Meraviglia, P Corsi, P Bagnarelli, P Almi, A Zoncada, S Paolucci, A Gonnelli, G Colao, D Tacconi, M Franzetti, M Ciccozzi, M Zazzi, C Balotta HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America. PLoS One. 2012;7(8):e42223. Epub 2012 Aug 2
- K Theys, K Deforche, J Vercauteren, P Libin, DA van de Vijver, J Albert, B Asjo, C Balotta, M Bruckova, RJ Camacho, B Clotet, S Coughlan, Z Grossman, O Hamouda, A Horban, K Korn, LG Kostrikis, C Kucherer, C Nielsen, D Paraskevis, M Poljak, E Puchhammer-Stockl, C Riva, L Ruiz, K Liitsola, JV Schmit, R Schuurman, A Sonnerborg, D Stanekova, M Stanojevic, D Struck, K van Laethem, AM Wensing, CA Boucher, AM Vandamme Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. Retrovirology 2012, 9:81 doi:10.1186/1742-4690-9-81
- V Cento, C Mirabelli, S Dimonte, R Salpini, Y Han, P Trimoulet, A Bertoli, V Micheli, G Gubertini, G Cappiello, A Spano, R Longo, M Bernassola, F Mazzotta, GM De Sanctis, XX Zhang, J Verheyen, A d'Arminio Monforte, F Ceccherini-Silberstein, CF Perno, V Svicher Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution. J Gen Virol. 2012 Oct 10
- MM Santoro, D Armenia, L Fabeni, M Santoro, C Gori, F Forbici, V Svicher, A Bertoli, L Dori, M Surdo, E Balestra, G Palamara, E Girardi, G Angarano, M Andreoni, P Narciso, A Antinori, F Ceccherini-Silberstein, CF Perno The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. Clin Microbiol Infect.;18(8):E289-98 (2012)
- MM Santoro, C Alteri, L Ronga, P Flandre, L Fabeni, F Mercurio, R D'Arrigo, C Gori, G Palamara, A Bertoli, F Forbici, R Salpini, E Boumis, V Tozzi, U Visco-Comandini, M Zaccarelli, M Van Houtte, T Pattery, P Narciso, A Antinori, F Ceccherini-Silberstein, CF Perno Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy. AIDS Res Hum Retroviruses 28(10):1285-93 (2012)
- D Armenia, I Vandenbroucke, L Fabeni, H Van Marck, V Cento, R D'Arrigo, L Van Wesenbeeck, F Scopelliti, V Micheli, B Bruzzone, S Lo Caputo, J Aerssens, G Rizzardini, V Tozzi, P Narciso, A Antinori, L Stuyver, CF Perno, F Ceccherini-Silberstein Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis.; 205(4):557-67 (2012)
2011
- L Wittkop, HF Günthard, F de Wolf, D Dunn, A Cozzi-Lepri, A de Luca, C Kücherer, N Obel, V von Wyl, B Masquelier, C Stephan, C Torti, A Antinori, F García, A Judd, K Porter, R Thiébaut, H Castro, AI van Sighem, C Colin, J Kjaer, JD Lundgren, R Paredes, A Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011 May;11(5):363-371
- V Svicher, C Alteri, A Artese, JM Zhang, G Costa, F Mercurio, R D'Arrigo, S Alcaro, G Palù, M Clementi, M Zazzi, M Andreoni, A Antinori, A Lazzarin, F Ceccherini-Silberstein, CF Perno; on behalf of the OSCAR study group. Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage. Antivir Ther. 16(7):1035-1045 (2011)
- I Malet, S Fourati, C Charpentier, L Morand-Joubert, D Armenia, M Wirden, S Sayon, M Van Houtte, F Ceccherini-Silberstein, F Brun-Vézinet, CF Perno, D Descamps, A Capt, V Calvez, AG Marcelin The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype J Antimicrob Chemother. Sep 21. 66 (12): 2827-2830 (2011). IF 4.659, Citazioni 4
- C Alteri, MM Santoro, I Abbate, G Rozera, A Bruselles, B Bartolini, C Gori, F Forbici, N Orchi, V Tozzi, G Palamara, A Antinori, P Narciso, E Girardi, V Svicher, F Ceccherini-Silberstein, MR Capobianchi, CF Perno Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. J Antimicrob Chemother. 66(11):2615-23 (2011)
- AM Vandamme, RJ Camacho, F Ceccherini-Silberstein, A de Luca, L Palmisano, D Paraskevis, R Paredes, M Poljak, JC Schmit, V Soriano, H Walter, A Sönnerborg; European HIV Drug Resistance Guidelines Panel. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev. Apr-Jun; 13(2):77-108 (2011)
- I Malet, M Wirden, S Fourati, D Armenia, B Masquelier, L Fabeni, S Sayon, C Katlama, CF Perno, V Calvez, AG Marcelin, F Ceccherini-Silberstein F Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients. J Antimicrob Chemother. Jul; 66(7):1481-3 (2011)
- V Svicher, E Balestra, V Cento, L Sarmati, L Dori, I Vandenbroucke, R D'Arrigo, AR Buonomini, H Van Marck, M Surdo, P Saccomandi, W Mostmans, J Aerssens, S Aquaro, LJ Stuyver, M Andreoni, F Ceccherini-Silberstein, CF Perno HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Antiviral Res. Apr; 90(1):42-53 (2011)
2010
- A De Luca, M Prosperi, L Bracciale. Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options. Curr Opin HIV AIDS. 2010 Jan;5(1):27-37
- F Ceccherini-Silberstein, K Van Baelen, D Armenia, M Trignetti, E Rondelez, L Fabeni, F Scopelliti, M Pollicita, L Van Wesenbeeck, V Van Eygen, L Dori, L Sarmati, S Aquaro, G Palamara, M Andreoni, LJ Stuyver, CF Perno. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naïve patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother. 2010 Sep;54(9):3938-48.
- F Ceccherini-Silberstein, I Malet, L Fabeni, S Dimonte, V Svicher, R D'Arrigo, A Artese, G Costa, S Bono, S Alcaro, A d'Arminio Monforte, C Katlama, V Calvez, A Antinori, AG Marcelin, CF Perno. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naïve to integrase inhibitors. J. Antimicrob. Chemother. 2010 Nov; 65(11):2305-18
2009
- F Ceccherini-Silberstein, V Svicher, M Van Houtte. New Horizons in Resistance Interpretation. HIV and AIDS 2009; 10 June 2009, in press.
- MC Puertas, MJ Buzòn, A Artese, S Alcaro, L Menendez-Arias, CF Perno, B Clotet, F Ceccherini-Silberstein, J Martinez-Picado. Effect of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Polymorphism Leu-214 on Replication Capacity and Drug Susceptibility. Journal of Virology 2009; 83(15):7434-7439.
